Abivax S.A.
NASDAQ: ABVX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marc de Garidel
- Employees
- 69
- Headquarters
- Paris, France
- IPO year
- 2023
- Market cap
- $6.5B
- Website
- https://www.abivax.com
Loading ABVX…
Loading profile data…Frequently asked questions about ABVX
What does Abivax S.A. (ABVX) do?
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease...
Where does ABVX trade?
Abivax S.A. (ABVX) trades on the NASDAQ Global Market.
What sector is ABVX in?
Abivax S.A. (ABVX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Abivax S.A.?
Marc de Garidel is the chief executive officer of Abivax S.A. (ABVX).
Where is Abivax S.A. headquartered?
Abivax S.A. is headquartered in France.
Does ABVX pay a dividend?
Abivax S.A. (ABVX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ABVX go public?
Abivax S.A. (ABVX) completed its initial public offering in 2023.
Is ABVX an ADR?
Yes — ABVX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Abivax S.A. reporting and dividends follow the underlying issuer.